Monique Minnema MD, PhD

Prof Dr Monique C. Minnema was trained as an internist and hematologist at Academic Medical Center, Amsterdam, and the University Medical Center, Utrecht. She started working as a hematologist in 2005 at the Department of Hematology, UMC Utrecht, and was appointed full professor in 2019. She specializes in the diagnosis and treatment of B cell malignancies, especially plasma cell dyscrasis like Multiple Myeloma AL amyloidosis, and Waldenstrom Macroglobulinemia. Prof Minnema is the author of several national and international guidelines on the diagnosis and treatment of these diseases. She is the head supervisor of the hematology clinical research team, the hematology biobank, and the European expertise reference network (ERN) malignant hematology of the UMC Utrecht. Her main focus of clinical research is the development of novel therapies (both cellular and drug) developments for plasma cell dyscrasias.

Prof Dr Minnema is an active member of the HOVON working parties for Multiple Myeloma, Lymphoma, and IEC and the vice president of the Lunenburg Lymphoma Consortium (LLPC) for phase I/II studies. Examples of her work are the HOVON 104 trial for patients with AL amyloidosis first-line treatment, the clinical studies with the monoclonal antibody Daratumumab in relapsed Multiple Myeloma and newly diagnosed AL amyloidosis and anti-CD19 CAR T cells in relapsed Lymphoma. Her translational research focuses on 3D models to predict response to therapy and the use of combined immunotherapy for relapsed multiple myeloma. She was a member of the organizing committee of the Waldenström workshop in Amsterdam in 2016 and is co-initiator of the yearly Immune Effector Cell and the Systemic Amyloidosis symposia.